ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Diagnostic utility of bony nasolacrimal duct area on computed tomography for differentiating malignant lacrimal tumors.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine whether the expansion ratio of the bony nasolacrimal duct on computed tomography (CT) can differentiate malignant lacrimal tumors from benign lesions and primary acquired nasolacrimal duct obstruction (PANDO).
methodsThe study retrospectively analyzed 19 patients with malignant lacrimal tumors and 195 with unilateral PANDO who visited the Kyushu University Hospital and underwent CT-dacryocystography between April 2018 and March 2023. Of the 195 PANDO cases, 14 that developed a lacrimal sac mass associated with chronic dacryocystitis were defined as the benign mass group. Clinical data including age, sex, tumor location and histopathology, and CT findings of the bony nasolacrimal duct were obtained via medical records.
resultsThe malignant tumor group included 12 males and 7 females, and the mean age was 54.7 years. The benign mass group included 7 males and 7 females, and the mean age was 67.5 years. The PANDO group included 39 males and 142 females, and the mean age was 70.3 years. Tumor locations in patients with malignant tumors, including overlapping sites, were the lacrimal sac in 17 cases, the nasolacrimal duct in 9, the canaliculus in 2, and the nasal cavity in 1. Histopathological diagnoses were squamous cell carcinoma in 8 cases, malignant lymphoma in 4, adenoid cystic carcinoma in 2, and 1 case each of sebaceous carcinoma, mucoepidermoid carcinoma, apocrine adenocarcinoma, rhabdomyosarcoma, and Langerhans cell histiocytosis. Tumor locations in patients with benign masses were the lacrimal sac in 11 cases, the nasolacrimal duct in 2, and the nasal cavity in 1. Histopathological diagnoses were inflammatory granulation tissue in 11 cases and cyst in 3. Median expansion ratios of the bony nasolacrimal duct (affected side/unaffected side) on axial CT were 167.5% in the malignant tumor group, 123.3% in the benign mass group, and 106.8% in the PANDO group.
conclusionMalignant lacrimal tumors showed considerably greater expansion of the bony nasolacrimal duct on CT. An expansion ratio of ≥ 150% may be a useful adjunctive marker for distinguishing malignant lacrimal tumors in clinical practice.
Indexed as
Identifiers
42105086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.